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ORIGINAL ARTICLE
Randomized phase III trial of low-molecular-weight
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Background: Coagulation activation and venous thromboembolism (VTE) are hallmarks of malignant disease and represent a
major cause of morbidity and mortality in cancer. Coagulation inhibition with low-molecular-weight heparin (LMWH) may
improve survival specifically in small-cell lung cancer (SCLC) patients by preventing VTE and tumor progression; however,
randomized trials with well-defined patient populations are needed to obtain conclusive data. The aim of RASTEN was to
investigate the survival effect of LMWH enoxaparin in a homogenous population of SCLC patients.
Patients and methods: We carried out a randomized, multicenter, open-label trial to investigate the addition of enoxaparin at
a supraprophylactic dose (1 mg/kg) to standard treatment in patients with newly diagnosed SCLC. The primary outcome was
overall survival (OS), and secondary outcomes were progression-free survival (PFS), incidence of VTE and hemorrhagic events.
Results: In RASTEN, 390 patients were randomized over an 8-year period (2008–2016), of whom 186 and 191 were included in
the final analysis in the LMWH and control arm, respectively. We found no evidence of a difference in OS or PFS by the addition
of enoxaparin [hazard ratio (HR), 1.11; 95% confidence interval (CI) 0.89–1.38; P¼ 0.36 and HR, 1.18; 95% CI 0.95–1.46; P¼ 0.14,
respectively]. Subgroup analysis of patients with limited and extensive disease did not show reduced mortality by enoxaparin.
The incidence of VTE was significantly reduced in the LMWH arm (HR, 0.31; 95% CI 0.11–0.84; P¼ 0.02). Hemorrhagic events
were more frequent in the LMWH-treated group but fatal bleedings occurred in both arms.
Conclusion: LMWH enoxaparin in addition to standard therapy did not improve OS in SCLC patients despite being
administered at a supraprophylactic dose and despite resulting in a significant reduction in VTE incidence. Addition of LMWH
cannot be generally recommended in the management of SCLC patients, and predictive biomarkers of VTE and LMWH-
associated bleeding in cancer patients are warranted.
Key words: small-cell lung cancer, low-molecular-weight heparin, venous thromboembolism, enoxaparin, coagulation,
randomized phase III trial
Introduction
Lung cancer is the most common type of cancer worldwide, and
despite medical advances, mortality is high representing 1/5 of
cancer-related deaths [1]. SCLC accounts for 15% of all lung
cancer cases [2] and is characterized by neuroendocrine activity
and early metastasis. Although most patients show an initial good
treatment response, the prognosis is poor with 5-year survival
rates of<10%.
Venous thromboembolism (VTE) is a well-recognized compli-
cation in malignancy and a major contributor to cancer-
associated mortality and morbidity [3, 4]. Coagulation activation
is intimately related to tumor development, which has been
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mechanistically linked to the induction of tissue factor (TF), i.e.
the main initiator of coagulation [5, 6]. Low-molecular-weight
heparin (LMWH) binds to antithrombin-III and potentiates its
inhibition of procoagulant factor Xa [7]. Experimental evidence
suggests that LMWH has antitumor effects via, e.g. inhibition of
angiogenesis and metastasis [8–10]. This has prompted studies to
evaluate antitumor effects of heparin in patients, which have pro-
vided contradictory results [11]. An early meta-analysis showed a
reduced mortality among cancer patients receiving LMWH as
treatment of VTE [12], supported by a retrospective analysis of
the CLOT study showing that LMWH compared with coumarin-
derivative as treatment of VTE significantly reduced 1-year mor-
tality in patients with nonmetastatic disease [13]. Similarly, two
randomized trials comparing prophylactic LMWH to placebo in
patients with advanced malignancy reported improved survival
particularly in patients with a favorable prognosis [14, 15].
Interestingly, several reports suggest a particular survival bene-
fit with anticoagulation therapy in patients with SCLC [16, 17].
In a small randomized clinical trial (N¼ 84), Altinbas et al.
showed a median survival of 13 months in the LMWH group
compared with 8 months in the control group [16], and Lebeau
et al. [17] reported an improved survival of 317 days with the
addition of unfractionated heparin as compared with 216 days in
patients receiving standard chemotherapy alone. A Cochrane
report concluded that among a heterogeneous group of cancer
patients with no therapeutic or prophylactic indication for anti-
coagulation, increased 1-year survival with LMWH was uniquely
seen in SCLC patients [18], which was supported by a meta-
analysis of nine separate studies [19]. However, a recent random-
ized trial showed no survival benefit by the addition of LMWH to
standard care in a large population of lung cancer patients with
mixed histology [20]. Importantly, most of the above studies
were carried out with the LMWH dalteparin administered at a
prophylactic dose, which may be suboptimal for the tumor-in-
hibiting effects [10, 14, 16, 20]. Although LMWHs (dalteparin,
enoxaparin, and tinzaparin) have similar antithrombotic effects,
they have distinct pharmacological properties and may differenti-
ate in their ability to inhibit metastasis [21].
The aim of the RASTEN trial was to investigate whether
addition of LMWH enoxaparin at a supraprophylactic dose
to standard treatment improves survival rates compared with
standard treatment in a homogenous group of SCLC patients.
Patients and methods
Study design
RASTEN is a randomized-phase-III-study-of-standard-treatment-with-
or-without-the-addition-of-enoxaparin in SCLC (ClinicalTrials.gov:
NCT00717938), which was initiated and conducted by the Swedish Lung
Cancer Study Group. In this international, open-label trial, patients were
enrolled at 23 different centers (17 in Sweden, 5 in Canada and 1 in
Denmark). Patients were included with histologically or cytologically
verified SCLC of all stages, age 18 years or above, World Health
Organisation performance status 0–3, platelet count >100  109/l and
standard coagulation parameters within normal ranges. Key exclusion
criteria were prior systemic chemotherapy, concomitant anticoagulant
treatment except acetylsalicylic acid or clopidogrel, active bleeding or
high risk of clinically significant bleeding, pregnancy or lactation, or
other known contraindications to enoxaparin. All eligible patients gave
written informed consent before study entry. The study was carried out
according to the ICH/GCP guidelines and in agreement with the Helsinki
declaration and was approved by Läkemedelsverket (MPA) and the local
ethics committee, Lund University.
Randomization
Patients were randomized 1 : 1 between a control arm receiving standard
treatment and an intervention arm receiving standard treatment with the
addition of enoxaparin. Patients were stratified according to perform-
ance status, disease stage, age, gender and study center. The randomiza-
tion procedure was conducted at the Clinical Research Unit at Lund
University Hospital, using a computer algorithm.
Treatments
Standard therapy included a platinum compound and a topoisomerase
inhibitor administered for four to six cycles according to local guidelines.
Radiotherapy was given depending on disease extent and response to
chemotherapy, following local protocols. In the intervention arm, enoxa-
parin was given at 1 mg/kg as daily subcutaneous injections. The study
drug was started on day 1 of chemotherapy and continued until the 21st
day of the last chemotherapy cycle. To measure compliance, patients
were instructed to bring the empty syringe packages to each study visit,
and reasons for treatment interruptions were recorded. Anticoagulation
at therapeutic or temporary prophylactic dosages was allowed if clinically
indicated.
Follow-up
Patients were seen before start of each chemotherapy cycle. After comple-
tion of treatment, follow-up was carried out at 8 weekly intervals and
included clinical examination and a chest X-ray at a minimum, or
according to local guidelines.
End points
The primary end point, overall survival (OS), was defined as the date of
randomization to the date of death from any cause. For patients not re-
ported dead, information regarding vital status was confirmed from each
study center before data collection cut-off at 4 April 2017, at which point
the follow-up was censored for all patients still alive. Secondary outcomes
included progression-free survival (PFS) measured from the date of ran-
domization to the date of objective or clinical progression or death from
any cause, whichever came first. VTE and hemorrhagic events were
graded according to NCI-CTCAE3.0 criteria [22]. VTE diagnosis was
made by routine examination according to local protocol. The study
treatment was stopped permanently in case of a major hemorrhage,
defined as a decrease in hemoglobin >20 g/l or requiring transfusion of
two or more units of blood, any intracranial hemorrhage, VTE requiring
therapeutic anticoagulation, a persistent decrease in platelets <50  109
g/l or any other reason at the investigator’s discretion.
Statistical analyses
All patients initiating the first treatment cycle were included in the
statistical analysis according to intention to treat (ITT). Patients who
withdrew from the study were included in the ITT analyses, but their
follow-up times were censored at the date of withdrawal of consent.
Assuming exponentially distributed survival times, an accrual period
of 78 months and an additional follow-up of 12 months thereafter, 195
patients per arm would be required to have 80% power to detect an
increase in one-year survival rate from 35% to 46% in the intervention
arm at the alpha level 5% with a two-sided log rank test. Due to a slower
inclusion rate than initially expected, the protocol was amended
(study protocol version 8.0) and approval from the MPA and ethics
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committee was given to extend the study period. The statistics packages
SPSSv22 and STATA14.1 were used for data analysis. Survival was esti-
mated using the Kaplan–Meier method and the log rank test was used to
compare the survival curves. Cox regression was used to quantify the ef-
fect of treatment on outcome [hazard ratio (HR) with 95% confidence
interval (CI)]. The statistical analysis of the primary outcome (OS) was
unadjusted, but a complementary multivariable analysis was carried out
to improve the precision in the treatment effect measure. Cumulative
incidence of first VTE, per treatment group, was calculated using a
standard method which accounts for death without VTE as a competing
event [23].
Results
Study population
Between July 2008 and March 2016, 390 patients were enrolled
with nine cases excluded due to other histology than SCLC and
four patients for other reasons (Figure 1). Four cases withdrew
consent after initiating treatment and their follow-up times were
censored from the withdrawal date. A total of 377 patients were
included in the ITT population; 186 in the LMWH enoxaparin
arm and 191 in the control arm. Median follow-up was
41 months (interquartile range, 21–81 months) for patients still
alive. Baseline characteristics were comparable between both
arms (Table 1).
In the LMWH and control groups, respectively, 158 (85%) and
166 (87%) patients completed four or more cycles of chemother-
apy. The proportion of patients receiving radiotherapy was
similar with the exception of radiation towards metastatic lesions
where the control group was overrepresented. Treatment
summary is shown in supplementary Table S1, available at
Annals of Oncology online. Approximately 85% of the patients
in the enoxaparin group reported full adherence after each
treatment cycle and the temporary cessation of LMWH was on
average only 7 days.
Patient outcome
The primary end point, median OS, was 10.6 months in the
LMWH group and 11.3 months in the control group (HR, 1.11;
95% CI 0.89–1.38; P¼ 0.36) (Figure 2). Stratification for study cen-
ter and adjustment for age, gender, disease stage and performance
status gave a HR of 1.14 (95% CI 0.91–1.45; P¼ 0.26). The 1-year
survival rates were 48% and 47% in the LMWH and control groups,
respectively (HR, 0.98; 95% CI 0.74–1.30; P¼ 0.92).
The median OS was 17.8 and 8.6 months in patients with lim-
ited disease (LD) and extensive disease (ED), respectively
(P< 0.001). There were no survival differences between the treat-
ment arms when analyzing the subgroups depending on disease
stage (Figure 3). The addition of LMWH had no significant effect
on PFS (HR, 1.18; 95% CI 0.95–1.46; P¼ 0.14) (supplementary
Figure S1, available at Annals of Oncology online).
Enrolled in clinical trial
(N=390)
LMWH, enoxaparin
(N=195)
Excluded (N=9)
Incorrect diagnosis (N=6)
Abnormal coagulation
Parameters (N=1)
Study treatment not initiated,
Patient choice (N=1)
Administrative error (N=1)
Included in analysis
(N=186)
Included in analysis
(N=191)
No LMWH
(N=195)
Excluded (N=4)
Incorrect diagnosis (N=3)
Abnormal coagulation
parameters  (N=1)
Figure 1. CONSORT diagram of the RASTEN study population.
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VTE and hemorrhagic events
VTE and hemorrhagic events are listed in supplementary Table
S2, available at Annals of Oncology online. The VTE incidence was
significantly higher in the control arm where 16 patients (8.4%)
developed a VTE compared with 5 (2.7%) in the LMWH group
(P¼ 0.02). Two of the control patients developed fatal pulmon-
ary embolization. The cumulative incidence of VTE at 6 months
was 2.5% and 8.5% in the LMWH and control arms, respectively
(HR, 0.31; 95% CI 0.11–0.84; P¼ 0.02) (Figure 4).
Hemorrhagic events were reported in 27 cases in the LMWH
group. However, the majority were considered clinically non-
relevant (CTC grades 1–2) [22], whereas three patients suffered
fatal pulmonary hemorrhages. In the control group, eight pa-
tients experienced hemorrhagic events, including one fatal. The
distribution of other adverse events was equal between the treat-
ment arms (supplementary Table S3, available at Annals of
Oncology online).
Discussion
Studies on the tumor-promoting effects of the coagulation sys-
tem have provided a strong rationale for further investigations on
the role of LMWH in cancer treatment [8–11, 24–25]. However,
conflicting results from clinical studies reflect the need for
randomized trials with well-defined patient populations to ob-
tain conclusive data. The RASTEN study is, to our knowledge,
the largest trial that investigates the survival effect of LMWH in a
patient population with a homogenous tumor histology, SCLC,
which differs significantly from non-SCLC [26]. Further, this is
the only randomized controlled trial that investigates the antitu-
mor effect of LMWH used at a higher, supraprophylactic dose.
We found that the addition of enoxaparin to standard therapy
does not improve survival in SCLC patients. This was true
for patients with LD as well as ED, and in spite of a significant
reduction of VTE events.
Aggressive tumors are characterized by poorly perfused areas
with hypoxia-induced overexpression of TF and fVIIa [5, 6, 27]
that, independently of blood clot formation, can promote tumor
progression via activation of protease-activated receptors (PARs)
[28]. The lack of an antitumoral effect of LMWH in spite of
reduced systemic thrombosis may thus in part be related to poor
distribution to the procoagulant, hypoxic tumor niche, or to the
inability of LMWH to target coagulation-dependent signaling.
LMWH may offer a multitargeted strategy with simultaneous
Table 1. Baseline characteristics of the study population
Enoxaparin
(N 5 186)
Control
(N 5 191)
Age, years
Median 6 SD 67 6 7.9 68 6 8.5
IQR 62–72 62–73
Gender, n (%)
Female 108 (58) 109 (57)
Male 78 (42) 82 (43)
Performance status, n (%)
0–1 134 (72) 136 (71)
2–3 52 (28) 55 (29)
Disease stage, n (%)
Limited 72 (39) 78 (41)
Extensive 114 (61) 113 (59)
Biochemistry, median (IQR)
Hemoglobin, g/l 132 (122–146) 134 (123–143)
Leukocyte count, 109/l 9.5 (7.4–12.3) 9.7 (7.6–12.7)
Platelet count, 109/l 353 (274–445) 334 (262–419)
Sodium, mmol/l 138 (135–140) 138 (135–140)
Potassium, mmol/l 4.1 (3.9–4.5) 4.2 (4.0–4.5)
Serum creatinine, mmol/l 65 (57–75) 66 (56–80)
IQR, interquartile range.
1.00
Control: median survival 11.3 months
Enoxaparin: median survival 10.6 months
HR = 1.11, 95%CI: 0.89-1.38, P=0.36
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Figure 2. Kaplan–Meier curve of overall survival by treatment arm.
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inhibition of, e.g., heparanase, vascular endothelial growth
factor-A, fibroblast growth factors and platelet-derived growth
factors [8, 10, 24]; however, the net effect of LMWH interactions
within the complex tumor microenvironment is difficult to pre-
dict [29]. Specifically, a relatively low heparin concentration can
stabilize protein ligands to potentiate their functional activity,
whereas a higher concentration may compete with ligand inter-
actions and down-stream functional effects on, e.g., angiogenesis
and metastasis [24]. This argues for a relatively high dose of
LMWH when repurposed as an anticancer agent, which was our
rationale for investigating LMWH at an increased dose instead of
the prophylactic dose used in previous studies. A potential
drawback is the enhanced risk of bleeding complications;
however, fatal bleedings occurred at a low incidence in both
groups (N¼ 3 and 1, in the enoxaparin and control arm, respect-
ively). A potential overestimation of total hemorrhages in the
enoxaparin group may stem from a more vigilant registration of
low grade events in the treatment arm.
1.00
Limited disease Extensive disease
Control
Enoxaparin
Control
Enoxaparin
HR = 1.17, 95%CI: 0.80-1.70 HR = 1.07, 95%CI: 0.82-1.40
P=0.63P=0.41
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Figure 3. Kaplan–Meier curves of overall survival by disease extent according to treatment arm.
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Figure 4. Cumulative incidence of first venous thromboembolism (VTE).
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We chose an open-label study design to spare control patients
from placebo injections, and as the primary end point (OS) was
not associated with observation bias. Although the actual admin-
istration of the study drug cannot be ascertained, good adherence
is supported by the fact that VTE incidence was significantly
lower in the enoxaparin than in the control arm, which had two
cases of fatal pulmonary embolization. However, whether this
difference was clinically relevant in terms of decreased morbidity
and increased quality of life was not assessed in the present study.
Notably, addition of prophylactic LMWH in the treatment of pa-
tients with pancreatic cancer with a particularly high incidence of
VTE similarly showed a reduction in VTE incidence but no effect
on OS [30].
During the 8 years that the study was open for enrollment, the
treatment of SCLC remained unchanged. Thus, the treatment of
the control group is still relevant. A recent trial [31] indicated
that the addition of thoracic radiotherapy may improve outcome
in SCLC patients with ED; however, this has not yet been imple-
mented in clinical practice.
At present, the use of LMWH in cancer includes primary prophy-
laxis in patients at high risk of VTE, in patients diagnosed with VTE,
and as secondary prophylaxis [32]. The present study provides
strong support against a more general use of LMWH as a tumor-
inhibiting agent and underlines the need for risk biomarkers to
guide clinicians in tailoring individualized LMWH treatment [33].
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